Table 1.
Descriptive features of the studied groups (HIV ( +) and HIV ( -))
| Variable | HIV (+)(N = 74) | HIV (-)(N = 131) | Total(N = 205) | p | d |
|---|---|---|---|---|---|
| Gender | 0.006 | 0.388 | |||
| Male | 48 (64.9) | 59 (45.0) | 107 (52.2) | ||
| Female | 26 (35.1) | 72 (55.0) | 98 (47.8) | ||
| Age1 | 0.328 | 0.212 | |||
| 18 – 35 | 25 (34.2) | 42 (32.8) | 67 (33.4) | ||
| 36 – 50 | 41 (56.2) | 64 (50.0) | 105 (52.2) | ||
| >50 | 7 (9.6) | 22 (17.2) | 29 (14.4) | ||
| Smoking2 | 0.018 | 0.342 | |||
| Yes | 32 (45.7) | 37 (28.9) | 69 (34.8) | ||
| No | 38 (54.3) | 91 (71,1) | 129 (65.2) | ||
| ≥3 sites with PPD ≥ 5 mm and/or CAL ≥ 4 mm | 0.494 | 0.096 | |||
| Yes | 37 (50.0) | 72 (55.0) | 109 (53.2) | ||
| No | 37 (50.0) | 59 (45.0) | 96 (46.8) | ||
| VSB | |||||
| < 10% | 16 (21.6) | 22 (16.9) | 38 (18.6) | 0.407 | 0.116 |
| ≥ 10% | 58 (78.4) | 108 (83.1) | 166 (81.4) | ||
| BOP | 0.003 | 0.420 | |||
| < 10% | 17 (32.0) | 57 (43.5) | 74 (36.1) | ||
| ≥ 10% | 57 (77.0) | 74 (56.5) | 131 (63.9) | ||
| HIV viral load3 | |||||
| ≤ 1000 | 21 (58.3) | - | - | - | - |
| 1001 – 10000 | 7 (19.5) | - | - | - | - |
| > 10000 | 8 (22.2) | - | - | - | - |
| TCD4+lymphocytes4 | |||||
| < 200 | 12 (30.0) | - | - | - | - |
| 200 – 500 | 19 (47.5) | - | - | - | - |
| > 500 | 9 (22.5) | - | - | - | - |
Data are presented as n (%).
VSB visible supragingival biofilm, BOP bleeding on probing, PPD periodontal probing depth, CAL clinical attachment loss.
1Data refers to 201 patients [HIV (+) = 73; HIV (-) = 128].
2Data refers to 198 patients [HIV (+) = 70; HIV (-) = 128].
3Data refers to 36 patients HIV (+).
4Data refers to 40 patients HIV (+). Effect size (d): small (0.20 ≤ d <0.50), medium (0.50 ≤ d <0.80), and large (d ≥ 0.80) [21]